Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis
Open Access
- 31 October 2022
- journal article
- review article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (4) , 805-814
Abstract
Background: T cell receptor-engineered T cell (TCR-T) therapy has shown promising efficacy in advanced solid tumours. Lymphodepleting (LD) chemotherapy improves TCR-T cell therapy efficacy but is associated with significant toxicities. Evidence is sparse regarding the optimum LD regimen for TCR-T cell therapy in solid tumours. Methods: A systematic review was conducted of interventional, prospective clinical trials describing LD practices prior to TCR-T cell therapy in patients with advanced solid tumours. The objective was to define LD regimens administered prior to TCR-T cell therapy and their effects on specific safety and efficacy outcomes in this patient population. Results: Searches returned 484 studies, 19 (231 patients) met the eligibility criteria. Cyclophosphamide (cyclo) 60 mg/kg daily (2 days), plus fludarabine (fludara) 25 mg/m2 daily (5 days) was the most common LD regimen (38% of studies). Higher dose LD regimens were associated with increased pooled incidence rates of febrile neutropaenia compared to low dose (0.64, [95% Confidence interval (CI): 0.50–0.78], vs. 0.39 [95% CI: 0.25–0.53], respectively) but were not significantly associated with higher objective responses (odds ratio: 1.05, 95%CI: 0.60–1.82, p = 0.86). A major shortfall in safety data reporting was identified; determination of LD regimen effects on many safety outcomes was not possible. Conclusion: Standard consensus guidelines for the design and reporting of adoptive cell therapy (ACT) studies would facilitate accurate risk–benefit analysis for optimising LD regimens in patients with advanced solid tumours.Keywords
Funding Information
- This work was part of an application for the degree of Master of Science at Manchester University, funded by Owen Clinical Consulting Limited.
This publication has 45 references indexed in Scilit:
- A principal component analysis is conducted for a case series quality appraisal checklistJournal of Clinical Epidemiology, 2016
- Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal CancerClinical Cancer Research, 2015
- A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with ResponseClinical Cancer Research, 2015
- Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic MelanomaClinical Cancer Research, 2014
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene TherapyJournal of Immunotherapy, 2013
- Successful Treatment of Melanoma Brain Metastases with Adoptive Cell TherapyClinical Cancer Research, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluationInternational Journal of Epidemiology, 2008
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 2005
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988